Skip to content
No picture yet

Brukinsa 160 mg – DIN 02554267

Brukinsa is Zanubrutinib 160 mg (tablet), sold in Canada. It is used for mantle-cell lymphoma. It is supplied by Beone Medicines I GmbH. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.

Sold in Canada

Zanubrutinib 160 mg

Brand
Brukinsa
Strength
160 mg
Used for
Mantle-cell lymphoma
Form
Tablet
Manufacturer
Beone Medicines I GmbH
Drug class
Cancer medicine (kinase inhibitor)
Sold in
Canada
DIN
02554267

Source: Health Canada's Drug Product Database. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Zanubrutinib pills and guides

What is Zanubrutinib used for?

Zanubrutinib is used for mantle-cell lymphoma.

Medicine type
Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label

Mantle Cell Lymphoma

BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Waldenström's Macroglobulinemia

BRUKINSA is indicated for the treatment of adult patients with Waldenström's macroglobulinemia (WM).

Marginal Zone Lymphoma

BRUKINSA is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen.

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

BRUKINSA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Follicular Lymphoma

BRUKINSA is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy.

This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

From the FDA-approved label on DailyMed (published Sep 14, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your medicine? Check the box

  • The box or bottle shows DIN 02554267.
  • It names Brukinsa, Zanubrutinib 160 mg.
  • A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.

Sold in Canada as Brukinsa by Beone Medicines I GmbH.

In Canada: prescription only.

Ingredients

Active: Zanubrutinib

Other Zanubrutinib pills